亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Effects of CD19 CAR T Cell Therapy on Quality of Life and Direct Healthcare Costs in Systemic Lupus Erythematosus: A Preliminary Analysis

医学 生活质量(医疗保健) CD19 内科学 免疫学 疾病 汽车T细胞治疗 系统性红斑狼疮 红斑狼疮 T细胞 物理疗法 细胞疗法 年轻人 自身免疫性疾病 重症监护医学 结缔组织病 临床试验 免疫病理学 梅德林 医疗保健 社会经济地位 痹症科 儿科 全身性疾病 肿瘤科
作者
Jule Taubmann,Melanie Hagen,Fabian Müller,Andreas Wirsching,Selahattin Alp Temiz,Simon Völkl,Michael Aigner,Ricardo Grieshaber‐Bouyer,Andréas Mackensen,Georg Andreas Schett
出处
期刊:The Journal of Rheumatology [The Journal of Rheumatology Publishing Company Limited]
卷期号:53 (1): 33-37 被引量:6
标识
DOI:10.3899/jrheum.2024-1301
摘要

OBJECTIVE: Patients with systemic lupus erythematosus (SLE) require long-term treatment and experience reduced quality of life (QOL). CD19 chimeric antigen receptor (CAR) T cell therapy can achieve sustained drug-free remission in patients with SLE. The impact of CAR T cell therapy on QOL and direct healthcare costs has not been evaluated. Here, we analyzed longitudinal QOL before and after CAR T cell therapy and performed an assessment of direct healthcare costs. METHODS: Physical and mental health were assessed using the standardized 36-item Short Form Health Survey before and 1 year after treatment. Annual direct healthcare costs were analyzed based on inpatient admissions, emergency department visits, outpatient visits, and prescription drug costs in the German healthcare service. RESULTS: A preliminary analysis was conducted on 8 patients with SLE (7 female, 1 male; age range 19-38 years) who received CAR T cell therapy and who were followed for > 2 years. CAR T cell therapy resulted in improvement in the QOL in all patients. The most notable improvement was observed in physical health (from 22.4% to 75.5%), although mental health also improved (from 24.7% to 63%). QOL values rose to the level of a healthy comparison cohort. Additionally, CAR T cell therapy led to a substantial decrease in annual direct healthcare costs from €29,672/year (US $34,353/year) to €3094/year ($3582/year) after treatment. CONCLUSION: In addition to clinical efficacy, in this preliminary cohort, CD19 CAR T cell treatment improves QOL in patients with SLE and may substantially reduce the direct socioeconomic burden associated with active disease by > 90%.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
anniver732发布了新的文献求助10
2秒前
anniver732发布了新的文献求助10
2秒前
anniver732发布了新的文献求助10
2秒前
十四发布了新的文献求助10
3秒前
迷人宛亦发布了新的文献求助10
4秒前
5秒前
sailor发布了新的文献求助10
6秒前
molihuakai的应助被科研通管家采纳,获得10
7秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
7秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
7秒前
null的应助被科研通管家采纳,获得10
7秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
7秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
7秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
8秒前
天天快乐的应助被科研通管家采纳,获得10
8秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
8秒前
嘻嘻哈哈的应助被科研通管家采纳,获得10
8秒前
16秒前
sailor完成签到,获得积分10
19秒前
可爱的函函的应助被DRJ采纳,获得10
23秒前
踏实的又夏完成签到 ,获得积分10
23秒前
共享精神的应助被sailor采纳,获得10
25秒前
36秒前
42秒前
涛1118发布了新的文献求助10
43秒前
笑哈哈完成签到,获得积分10
43秒前
单纯的天抒完成签到,获得积分10
46秒前
47秒前
dalang完成签到 ,获得积分10
49秒前
顾矜的应助被DRJ采纳,获得10
49秒前
caca完成签到,获得积分0
51秒前
anew_tape发布了新的文献求助10
52秒前
Yyusx完成签到 ,获得积分10
55秒前
傲娇曼岚完成签到,获得积分10
1分钟前
1分钟前
十四完成签到,获得积分10
1分钟前
1分钟前
舒心的以莲完成签到,获得积分10
1分钟前
Cherie77发布了新的文献求助10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165968
求助须知:如何正确求助?哪些是违规求助? 9559396
关于积分的说明 21749984
捐赠科研通 7756746
什么是DOI,文献DOI怎么找? 3429092
关于科研通互助平台的介绍 2553386
邀请新用户注册赠送积分活动 2473667